Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for … – PR Newswire (press release)

Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for
PR Newswire (press release)
Montelukast is FDA-approved for treatment of asthma and allergic rhinitis. It works by inhibiting leukotrienes, the chemicals that cause inflammation. Montelukast is considered a second line of defense against asthma or allergic rhinitis.

and more »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *